Venuzuela

Jump to

No disturbing trend in Dr Reddy's numbers except topline: Expert

Shetty says that she has her doubts on a possible revival of revenues saying that the eight drugs bought from Teva for the US market, will take till 2019 to affect Dr Reddy's revenues.
Here are Edelweiss' 3 concerns that could hit Dr Reddy's

An increase in competition in the US business is going to lead to pricing pressure for Dr Reddy's Laboratories. This can lead to a fall in margins for the pharma company by about 250-350 basis points, says Deepak Malik, Associate Director, Edelweiss Securities.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Venuzuela

No disturbing trend in Dr Reddy's numbers except topline: Expert

Here are Edelweiss' 3 concerns that could hit Dr Reddy's